OptiBiotix Health PLC Transfer of certain SkinBioTherapeutics plc shares (0909H)
29 Julio 2019 - 10:03AM
UK Regulatory
TIDMOPTI
RNS Number : 0909H
OptiBiotix Health PLC
29 July 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Transfer of certain SkinBioTherapeutics plc shares
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, cardiovascular disease and
diabetes, announces that a portion of its shareholding in
SkinBioTherapeutics plc consisting of 20,438,496 ordinary shares
representing 15.88% of SkinBioTherapeutics plc's total issued share
capital, have been dematerialised and transferred to a nominee
CREST account (Pershing Nominees). OptiBiotix plc remains the
beneficial owner of the transferred 20,438,496 ordinary shares.
There has been no change in the Company's overall beneficial
holding of its SkinBioTherapeutics plc shareholding which in total
consists of 49,794,190 representing 38.9% of SkinBioTherapeutics
plc's total issued share capital.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash / Kate Bannatyne (Corporate Finance)
Tel: 020 7220 0500
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGMGZNKLMGLZM
(END) Dow Jones Newswires
July 29, 2019 11:03 ET (15:03 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024